Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...
HYDERABAD: Dr Reddy’s Labs on Wednesday said its subsidiary, Dr Reddy’s Labs SA, has entered into commercialisation and ...
On a sweltering July day in Springfield, Heather Anderson, a 47-year-old resident of the capital city, walked out onto her front porch and into a nightmare.
Zacks Investment Research on MSN4d
Here's How to Play JNJ Stock as it Announces $55B US Investment PlanJ&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...
Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback